Did You Know...
...that the video game, Pong, was invented by a guy who graduated at the bottom of his engineering class? Nolan Bushnell spent more time running the games at a local amusement park than he did on his studies at the University of Utah. His dreams of working for Disney's amusement empire were dashed when the company wouldn't hire him. Taking a boring job, Nolan daydreamed about electronic versions of popular games. He invented Pong, the first video game, and went on to found Atari Co.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8133861 | Systemic purine administration: modulating axonal outgrowth of central nervous system neurons Methods for modulating the axonal outgrowth of central nervous system neurons are provided by means of internalized purine administration such as by intravenous, intraarterial, subcutaneous, intramuscular, intraperitoneal, and intrapleural administration. The method... | 03/13/2012 |
| 8093226 | Cytostatic 7-deazapurine nucleosides The invention provides compounds of formula I: wherein R1 and R2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic... | 01/10/2012 |
| 8088752 | Methods for metabolic modulation Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are e... | 01/03/2012 |
| 8076310 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated, oxygen-containing or sulfur-containing ring coupled to a heterocycli... | 12/13/2011 |
| 8058258 | Methods for cancer therapy and stem cell modulation The present invention relates to a method of inducing apoptosis in a tumour cell as well as modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of general formul... | 11/15/2011 |
| 8048865 | Method and pharmaceutical to treat spinal discs Methods for reducing chronic pain caused by a disrupted spinal disc are described. In one method, a physiologically acceptable amount of an injectable is injected into the disc. The injectable is obtained from a stock solution comprising chondroitin sulphate, glucos... | 11/01/2011 |
| 8030293 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 10/04/2011 |
| 7989430 | Antibacterial agents The invention provides compounds of formula (I) and salts thereof: R1-L-R2—B wherein R1, L, R2, and B have any of the values defined herein, as well as compositions comprising such compounds, and therapeutic methods comp... | 08/02/2011 |
| 7985740 | Purine derivatives as agonists of the adenosine A2A receptor The invention provides novel compounds which are agonists of the adenosine 2A receptor along with pharmaceutical compositions thereof, and methods of administering such compounds. ... | 07/26/2011 |
| 7943593 | Compositions comprising inhibitors of IMPDH enzyme The present invention relates to compositions comprising an apoptosis inducing anti-cancer agent and an IMPDH inhibitor. This invention also relates to methods for inducing apoptosis and for treating tumors and cancers in mammals. ... | 05/17/2011 |
| 7935680 | Methods for modulating the axonal growth of central nervous system neurons Methods for modulating the axonal outgrowth of central nervous system neurons are provided. Methods for stimulating the axonal outgrowth of central nervous system neurons following an injury (e.g., stroke, Traumatic Brain Injury, cerebral aneurism, spinal cord injur... | 05/03/2011 |
| 7928085 | P-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-β-D-ribofuranosyl)-3H-thiazole[4,5-d]pyrimidine-2-one and methods for preparation The present disclosure relates to p-toluene sulfonic acid salt of 5-amino-3-(2′-O-acetyl-3′-deoxy-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one and to its use in treating conditions such as viral infections, tumors, and cancer. | 04/19/2011 |
| 7915232 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication The present invention relates to the use of nucleoside derivatives of formula Ia wherein the symbols are as defined in the specification, and of pharmaceutically acceptable salts thereof which inhibit HCV polymerase and are... | 03/29/2011 |
| 7867983 | Methods to protect skeletal muscle against injury Disclosed herein are compositions and methods for the treatment of skeletal muscle and/or the protection of skeletal muscle against injury. The adenosine A3 receptor has been identified as a new therapeutic target for the treatment of skeletal muscle. Ade... | 01/11/2011 |
| 7846912 | Deuterium-enriched nelarabine The present application describes deuterium-enriched nelarabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. ... | 12/07/2010 |
| 7820636 | Sugar intake promoters An object of the invention is to provide a substance that activates saccharide uptake in epidermal cells and is thus expected to be effective in promoting skin cell neogenesis and metabolism. The invention provides a promoter for saccharide uptake in epidermal kerat... | 10/26/2010 |
| 7820637 | Use of 5′-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection 5′-methylthioadenosine (MTA), its pharmaceutically acceptable salts and/or prodrugs may be used in the prevention and/or treatment of autoimmune diseases, such as, for example, Multiple Sclerosis (MS), as well as in the prevention and/or treatment of transplant re... | 10/26/2010 |
| 7812000 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of... | 10/12/2010 |
| 7795236 | Purine nucleoside derivative modified in 8-position and medical use thereof The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a... | 09/14/2010 |
| 7749980 | Non-nucleotide compositions and method for treating pain The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain... | 07/06/2010 |
| 7648967 | Mutagenic nucleoside analogs for the treatment of viral disease The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs. In particular, the invention provides isoguanosine nucleosides and derivatives thereof as well a method of increasing the mutation rate of a virus such as bovine v... | 01/19/2010 |
| 7635689 | Modified 2′ and 3′-nucleoside prodrugs for treating infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and ... | 12/22/2009 |
| 7635690 | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine The present invention discloses a method for treating HIV that includes administering β-D-D4FC or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location ... | 12/22/2009 |
| 7632825 | Methods of decreasing or preventing pain using spicamycin derivatives Methods of providing pain relief by administering a water-soluble derivative of spicamycin. Methods of using pain mediation agents are also provided. ... | 12/15/2009 |
| 7629328 | Nucleoside derivatives for treating hepatitis C virus infection Disclosed are methods for treating hepatitis C viral infections using deaza-purine compounds of Formula I: wherein W, W1, W2, Y, R1, Z, Y′ and R are as defined herein. ... | 12/08/2009 |
| 7625875 | 2′ and 3′-nucleoside prodrugs for treating infections 2′ and 3′-Prodrugs of 1′, 2′, 3′ or 4′-branched β-D or β-L nucleosides, or their pharmaceutically acceptable salts and derivatives are described, which are useful in the prevention and treatment of Flaviviridae infections and other related conditions. ... | 12/01/2009 |
| 7625876 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 12/01/2009 |
| 7618949 | Drug-eluting stents coated with P2Yreceptor antagonist compound The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the ste... | 11/17/2009 |
| 7612047 | Degradation-resistant mononucleoside phosphate compounds The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on ... | 11/03/2009 |
| 7608600 | Modified 2′ and 3′-nucleoside prodrugs for treating infections 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branched nucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and ... | 10/27/2009 |
| 7601701 | Compounds for the treatment of tobacco dependence and withdrawal The invention provides methods for treating or suppressing tobacco or nicotine usage or dependence involving administration of a therapeutically-effective amount of a cytosine-containing or cytidine-containing compound, creatine-containing compound, adenosine-contai... | 10/13/2009 |
| 7589075 | Use of an adenosine A3 receptor agonist for inhibition of viral replication The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In particular, the invention provides a composition and method for inhibiting v... | 09/15/2009 |
| 7582616 | Nucleoside transport inhibitors Compounds or compositions that are inhibitors and/or ligands of nucleoside transporters; and methods of treating cancer, heart disease and stroke, as well as AIDS and other infectious diseases. ... | 09/01/2009 |
| 7579331 | Method of improved diuresis in individuals with impaired renal function Disclosed is a pharmaceutical composition comprising a therapeutically effective amount of KW-3902, or a salt, ester, amide, metabolite, or prodrug thereof, and a non-adenosine modifying diuretic. Also disclosed are methods of inducing a diuretic effect in an animal... | 08/25/2009 |
| 7576068 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus This invention relates to methods for treating or preventing hepatitis C virus infections in mammals using Toll-Like Receptor (TLR)7 ligands and prodrugs thereof. More particularly, this invention relates to methods of orally administering a therapeutically effectiv... | 08/18/2009 |
| 7569555 | Method for stimulating the immune, inflammatory or neuroprotective response Cycic di-GMP, or a cyclic dinucleotide analogue thereof that has the same effect as cyclic di-GMP, stimulates or enhances immune or inflammatory response in a patient or enhances the immune response to a vaccine by serving as an adjuvant. Cyclic di-GMP, or a cyclic ... | 08/04/2009 |
| 7550442 | Nucleoside analog inhibitors of reverse transcriptase Compounds of formula (XXIII), or pharmaceutically acceptable salts or esters thereof, are inhibitors of reverse transcriptase: R4 is a nucleoside with Q substituting a 3′ hydroxyl group, and Q is a moiety of... | 06/23/2009 |
| 7462604 | Hair growth promotor composition A hair growth promotor which is an ethanol or aqueous ethanol preparation comprising, as active ingredients for a hair growth promotor, (A) at least one compound selected from fatty acids having a chain length of an odd number of carbon atoms, the derivatives of the... | 12/09/2008 |
| 7452870 | Drug-eluting stents coated with P2Yreceptor antagonist compound The present invention provides a P2Y12 receptor antagonist compound-eluting stent, wherein the stent is coated with one or more P2Y12 receptor antagonist compounds or a pharmaceutically acceptable salt, solvate, or hydrate thereof. When the ste... | 11/18/2008 |
| 7435724 | Degradation-resistant mononucleoside phosphate compounds The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on ... | 10/14/2008 |
